Final results of phase I/II trial of fractionated dose 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC)

被引：2
|
作者：
Tagawa, S. T. [1 ]
Sun, M. [2 ]
Sartor, O. [3 ]
Thomas, C. [4 ]
Molina, A. M. [1 ]
Sternberg, C. N. [5 ]
Nanus, D. M. [6 ]
Osborne, J. [7 ]
Bander, N. [8 ]
机构：
[1] Weill Cornell Med Ctr, Urol, Hematol & Med Oncol, New York, NY USA
[2] Weill Cornell Med Ctr, Hematol & Med Oncol, New York, NY USA
[3] Tulane Med Sch, Med Sch, New Orleans, AL USA
[4] Weill Cornell Med Ctr, Biostat, New York, NY USA
[5] Cornell Univ, Weill Cornell Med Coll, Dept Hematol & Oncol, New York, NY USA
[6] Weill Cornell Med Coll, Med, New York, NY USA
[7] Weill Cornell Med Ctr, Radiol, New York, NY USA
[8] Weill Cornell Med Ctr, Urol, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
600P
引用
收藏
页码：S645 / S645
页数：1
相关论文
共 50 条
  • [11] Promising 177Lu-PSMA-617 Therapy Results in Patients with Metastatic Castration-Resistant Prostate Cancer
    Brnjic, Antonio
    Frye, Sarah
    Botkin, Crystal
    Osman, Medhat
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [12] LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)
    Sandhu, Shahneen
    Joshua, Anthony M.
    Emmett, Louise
    Crumbaker, Megan
    Bressel, Mathias
    Huynh, Rhonda
    Banks, Patricia Diana
    Wallace, Roslyn
    Hamid, Anis
    Inderjeeth, Andrisha Jade
    Tran, Ben
    Azad, Arun
    Alipour, Ramin
    Kong, Grace
    Kumar, Aravind Ravi
    Saghebi, Javad
    Williams, Scott
    Akhurst, Timothy J.
    Hicks, Rodney J.
    Hofman, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [13] Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC)
    Vlachostergios, Panagiotis J.
    Goswami, Sukanya
    Niaz, Muhammad Junaid
    Thomas, Charlene
    Christos, Paul J.
    Osborne, Joseph
    Vallabhajosula, Shankar
    Molina, Ana M.
    Sternberg, Cora N.
    Singh, Sharon
    Tan, Angela
    Patel, Amie
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [14] 177Lu-PSMA-617 Treatment of Metastatic Castration-Resistant Prostate Cancer: Efficacy and Survival
    Demirci, E.
    Akyel, R.
    Sahin, O.
    Ocak, M.
    Aygun, A.
    Pehlivanoglu, H.
    Karayel, E.
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S202 - S203
  • [15] Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: A substudy of the VISION trial
    Kurth, Jens
    Herrmann, Ken
    Eiber, Matthias
    Rahbar, Kambiz
    Heuschkel, Martin
    Lassmann, Michael
    Jentzen, Walter
    Chicco, Daniela
    Messmann, Richard
    Sartor, A. Oliver
    Morris, Michael J.
    Krause, Bernd J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [16] Phase 3 Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer (VISION)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 3 - 5
  • [17] Phase 3 Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)
    Krause, B.
    de Bono, J.
    Chi, K. N.
    Fizazi, K.
    Herrmann, K.
    Rahbar, K.
    Tagawa, S. T.
    Nordquist, L. T.
    Vaishampayan, N.
    El-Haddad, G.
    Park, C. H.
    Beer, T. M.
    Perez-Contreras, W. J.
    DeSilvio, M.
    Kpamegan, E.
    Gericke, G.
    Messmann, R. A.
    Morris, M. J.
    Sartor, O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S63 - S63
  • [18] Cost Utility Analysis of 177Lu-PSMA-617 Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Germany
    Stargardt, T.
    Brinkmann, C.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S827 - S827
  • [19] Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial
    Ugo De Giorgi
    Maddalena Sansovini
    Stefano Severi
    Silvia Nicolini
    Manuela Monti
    Giorgia Gurioli
    Flavia Foca
    Chiara Casadei
    Vincenza Conteduca
    Monica Celli
    Valentina Di Iorio
    Daniele Calistri
    Federica Matteucci
    Finn Edler von Eyben
    Gerhardt Attard
    Giovanni Paganelli
    British Journal of Cancer, 2021, 125 : 1226 - 1232
  • [20] Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial
    De Giorgi, Ugo
    Sansovini, Maddalena
    Severi, Stefano
    Nicolini, Silvia
    Monti, Manuela
    Gurioli, Giorgia
    Foca, Flavia
    Casadei, Chiara
    Conteduca, Vincenza
    Celli, Monica
    Di Iorio, Valentina
    Calistri, Daniele
    Matteucci, Federica
    von Eyben, Finn Edler
    Attard, Gerhardt
    Paganelli, Giovanni
    BRITISH JOURNAL OF CANCER, 2021, 125 (09) : 1226 - 1232
12345